利奈唑胺序贯治疗儿童革兰阳性球菌急性血源性骨髓炎的回顾性研究
x

请在关注微信后,向客服人员索取文件

篇名: 利奈唑胺序贯治疗儿童革兰阳性球菌急性血源性骨髓炎的回顾性研究
TITLE:
摘要: 目的:观察利奈唑胺序贯治疗儿童革兰阳性球菌急性血源性骨髓炎的临床疗效及安全性。方法:采用回顾性研究方法,选择13例儿童革兰阳性球菌急性血源性骨髓炎患儿作为研究对象。患儿采用手术+抗生素降阶梯治疗方案,待患儿症状缓解、体温降至正常2周、各项实验室指标检查3次均正常后改为口服利奈唑胺序贯治疗方式(10 mg/kg,q8 h),观察其临床疗效、不良反应及治疗前后实验室检查指标的变化。结果:13例患儿中有11例在结束口服利奈唑胺后治愈,治愈率为84.62%,随访症状无复发;除1例患儿白细胞过低外,其余患儿的红细胞沉降率、C反应蛋白、外周血白细胞及中性粒细胞百分比经治疗后均降至正常。有3例患儿发生药品不良反应,不良反应发生率为23.08%。结论:利奈唑胺口服治疗儿童革兰阳性球菌急性血源性骨髓炎疗效较好,可改善患儿实验室检查指标,且相对安全,可作为一种序贯治疗方案应用于临床。
ABSTRACT: OBJECTIVE: To observe clinical efficacy and safety of linezolid sequential therapy for pediatric gram-positive coccus acute hematogenous osteomyelitis. METHODS: In retrospective study, 13 children with gram-positive coccus acute hematogenous osteomyelitis was collected as research subjects. They received surgery+antibiotics step-down therapy, i.g. linezolid sequential therapy 10 mg/kg orally, q8 h, after symptom relief, body temperature return to normal for 2 weeks and normal lab indexes for 3 times. Clinical efficacy, ADR and lab indexes were observed before and after treatment. RESULTS: Of 13 children, recovery rate of 11 receiving linezolid was 84.62%, no relapse was found in follow-up period; ESR, C-reaction protein, WBC and NEU% of all children returned to normal except one child suffered from low count of white cell. 3 children suffered from ADR with the incidence of ADR was 23.08%. CONCLUSIONS: Oral administration of linezolid is effective and safe for pediatric gram-positive coccus acute hematogenous osteomyelitis, improve lab index of children and can be utilized as sequential therapy plan in clinic.
期刊: 2016年第27卷第14期
作者: 路坦,刘晓潭,董玉珍,赵斌
AUTHORS: LU Tan,LIU Xiaotan,DONG Yuzhen,ZHAO Bin
关键字: 利奈唑胺;儿童;革兰阳性球菌;急性血源性骨髓炎;序贯治疗
KEYWORDS: Linezolid; Children; Gram-positive coccus; Acute hematogenous osteomyelitis; Sequential therapy
阅读数: 302 次
本月下载数: 5 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!